ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Tea drinkers have lower glaucoma risk

Why Is Chlorella Considered a Superfood?

Soy, cruciferous vegetables could help lower breast cancer treatment side effects

The Long-Term Benefits of Drinking Oolong Tea

Wonderful White Tea: A Drink Fit for an Emperor

Why You Should Try This Sweet-Smelling and Health-Boosting Essential Oil

Arnica: This Powerful Herb Promotes Various Kinds of Healing

Chamomile Tea: Why This Ancient Therapeutic Drink Still Stands Out Today

Get ‘Hooked’ on Cat’s Claw: The Many Benefits of This Amazonian Herb

Try Apple Cider Vinegar and Black Cumin Oil as Your Go-To Salad Dressing

 
Print Page
Email Article

Will new antiviral spell CURE for many with hepatitis C?

  [ 4 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 31, 2011


Boceprevir is a new type of direct-acting antiviral agent that specifically targets & inhibits hepatitis C virus replication.

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

"This study represents a remarkable advance and a potential cure for people with hepatitis C who have not responded to previous therapy,” says co-author Stuart C. Gordon, MD, chief of hepatology at Henry Ford.

“We will soon have a new standard of treatment for hepatitis C patients,” says Dr. Gordon. "This study ushers in a new era of drug development that will provide a host of antiviral agents to treat hepatitis C, and we are now witnessing dramatic and rapid advances in how we will be able to treat these patients."

The results of the global study were published Mar 31 by The New England Journal of Medicine. / .

Hepatitis C Facts

• There is currently no vaccine for hepatitis C.

• At least 3.2 million Americans (and 270-300 million worldwide) are infected with hepatitis C, a chronic viral disease affecting the liver.

• Most people who are infected with hepatitis C remain without symptoms for years, yet the virus persists in the liver of about 85% of those infected.

• The current standard antiviral treatments have been able to cure about half of those with persistent infection.

• If infection progresses to produce symptoms of advanced liver disease, it is often too late to offer the current treatment regimens.

• The infection may lead to scarring of the liver (cirrhosis), liver cancer or the need for liver transplant.

• The Centers for Disease Control and Prevention estimates that more than 12,000 people in the US die each year of liver disease and liver cancer associated with the hepatitis C virus.

• The virus was spread through contact with infected blood products before 1990; and often via injection drug use or the sharing of straws during the use of cocaine.

• Among immigrants to the U.S. from Asian, African, Middle Eastern and Eastern European countries, the virus may have been transmitted via the use of non-sterile glass syringes used for vaccination purposes.

Study Details

Boceprevir is a protease inhibitor, a new class of direct-acting antiviral agent that specifically targets and inhibits the replication of the hepatitis C virus. Peginterferon & ribavirin are the current standard of care.

In the study, researchers randomly assigned patients to one of three groups. In all three groups, patients received peginterferon and ribavirin (the current standard of care) for four weeks. Then:

• A control group (group 1) continued to receive only peginterferon–ribavirin for 44 additional weeks;

• Group 2 received boceprevir plus peginterferon–ribavirin for 32 weeks. Of this group, patients who'd had a detectable hepatitis C virus level at treatment week 8 received placebo plus peginterferon-ribavirin for an additional 12 weeks;

• And group 3 received boceprevir plus peginterferon–ribavirin for 44 weeks.

Study Results

Results showed the rate of sustained virologic response (loss of the virus) was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in the control group (21%).

Among patients with an undetectable hepatitis C virus level at treatment week 8, the rate of sustained virologic response was:

• 86% after 32 weeks of triple therapy,

• And 88% after 44 weeks of triple therapy.

A sustained virologic response generally translates into a long-term eradication of virus, or cure.

"We can conclude that boceprevir, when added to peginterferon and ribavirin, leads to high rates of sustained virologic response in difficult-to-treat patients,” explains Dr. Gordon.

In an accompanying article in the same issue of The New England Journal of Medicine, treatment of previously untreated hepatitis C patients with the same three-drug cocktail likewise showed significantly higher response rates than the current two-drug regimen.

The study was funded by Schering-Plough (now Merck).

_____

Source: Henry Ford Health System news release, Mar 30, 2011




Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Ultra ATP+, Double Strength Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

The Genetic Mutation That May Compromise Your Health - And What to Do About It The Genetic Mutation That May Compromise Your Health - And What to Do About It
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map